tumor regression

Related by string. tumor regressions * Tumor . Tumors . TUMOR . tumors : malignant brain tumor . cancerous brain tumor . battling brain tumor . brain tumor / Regression . regressions : regression analyzes . linear regression . multivariate logistic regression . multivariate regression analysis * induced tumor regression . induce tumor regression . measurable tumor regressions *

Related by context. All words. (Click for frequent words.) 77 tumor shrinkage 76 tumor regressions 72 complete remissions 68 cytogenetic responses 67 xenograft models 66 evaluable patients 66 partial remissions 66 cytogenetic response 66 antitumor activity 66 remission CR 65 durable remissions 65 heavily pretreated patients 65 Tumor shrinkage 65 imatinib therapy 65 patients evaluable 64 complete cytogenetic 64 anti leukemic 64 heavily pretreated 64 CR CRu 63 liver metastases 63 complete cytogenetic response 63 lung metastases 63 viral suppression 63 mg kg dose 63 bleomycin 63 antitumor effects 62 neurologic progression 62 MCyR 62 RECIST criteria 62 pCR 62 oblimersen 62 orthotopic 62 inhibited tumor 62 chemoradiotherapy 62 metastatic lesions 62 pomalidomide 61 tumor recurrence 61 CCyR 61 dose limiting toxicities 61 mTOR inhibitors 61 chlorambucil 61 pegylated liposomal doxorubicin 61 leukemia AML 61 decitabine 61 paraprotein 61 tumor resection 61 locoregional disease 61 HGS ETR1 61 viral kinetics 61 transgene expression 61 mammary tumors 61 elacytarabine 61 docetaxel chemotherapy 60 telomerase inhibition 60 potent antitumor activity 60 follicular lymphomas 60 Bezielle 60 cytoreduction 60 antitumour activity 60 metastatic RCC 60 virological response 60 evaluable subjects 60 tumor necrosis 60 IFN α 60 lenalidomide Revlimid R 60 CA4P 60 virologic response 60 progression TTP 60 antiviral activity 60 NNRTI resistance 60 sustained virological response 60 CRp 60 evaluable 60 molecular remissions 60 DLTs 60 systemically administered 60 IFN alpha 59 dose cohorts 59 delayed CINV 59 bortezomib 59 interferon IFN 59 relapsed MM 59 axitinib 59 teriflunomide 59 disease progression 59 bendamustine 59 hematologic toxicity 59 PSADT 59 hematologic 59 biochemical relapse 59 DAPT 59 immune reconstitution 59 splenectomized patients 59 neoadjuvant chemotherapy 59 Immunohistochemical analysis 59 tumor progression 59 PASI scores 59 glioblastoma tumors 59 FLT3 ITD 59 estramustine 59 favorable pharmacokinetic profile 59 xenograft tumors 59 colorectal tumors 59 cytotoxicity 59 irinotecan chemotherapy 59 FOLFIRI 59 huN# DM1 59 vivo efficacy 59 etoposide 59 nodular partial response 59 DXL# 59 locoregional recurrence 59 Partial Responses 59 demonstrated antitumor activity 59 5FU 59 lung metastasis 59 octreotide 59 distant metastasis 59 clinically meaningful improvement 59 antitumor effect 58 carboplatin paclitaxel 58 inhibitory effects 58 EGF receptor 58 nab paclitaxel 58 mutated KRAS 58 adriamycin 58 ovarian carcinoma 58 androgen suppression 58 remyelination 58 trastuzumab Herceptin ® 58 ribavirin RBV 58 HER2 overexpression 58 vitro experiments 58 xenograft 58 neointimal hyperplasia 58 FOLFOX4 58 antitumor 58 sustained virologic response 58 CIMZIA ™ 58 daunorubicin 58 leukemia ALL 58 EGFRvIII 58 virological failure 58 plasma uric acid 58 epithelial tumors 58 CR nPR 58 malignant transformation 58 ENMD # 58 oral bioavailability 58 imetelstat 58 lung fibrosis 58 radiographic progression 58 cardiac toxicity 58 azacytidine 58 intravesical 58 potent inhibition 58 intracranial hemorrhage ICH 58 trabectedin 58 CIMZIA TM 58 renal tumors 58 p# activation 58 cisplatin chemotherapy 58 immunological responses 58 IFN gamma 58 antitumor efficacy 58 preoperative chemotherapy 58 gemcitabine carboplatin 58 FluCAM 58 gemcitabine cisplatin 58 ER CHOP 58 4mg/kg 58 HBV DNA 58 superficial bladder cancer 58 Notch1 58 milatuzumab 58 gemcitabine 58 cisplatin resistant 58 rindopepimut 58 neurotrophic 58 #ME# 58 response CCyR 57 KRAS wild 57 steroid dexamethasone 57 endostatin 57 familial ALS 57 postoperative chemotherapy 57 pyrazinamide 57 DFMO 57 metastatic lung cancer 57 anterior uveitis 57 systemic toxicity 57 bone metastasis 57 neoadjuvant 57 TACE 57 microtubule targeting 57 virologic responses 57 posaconazole 57 OXi# 57 chemoradiation 57 B7 H3 57 nephrotoxic 57 riociguat 57 PegIFN RBV 57 busulfan 57 CYT# potent vascular disrupting 57 dose escalation 57 colorectal liver metastases 57 topotecan 57 liver metastasis 57 plus dexamethasone 57 GBM tumors 57 LHRH agonists 57 adalimumab 57 follicular lymphoma 57 mesotheliomas 57 peripheral blood mononuclear 57 nadolol 57 response pCR 57 alkylating agent 57 seliciclib 57 EGFR TKI 57 HBeAg seroconversion 57 #mg dose [002] 57 relapsed MCL 57 KRAS mutations occur 57 Doxil ® 57 pancreatic adenocarcinoma 57 tumor xenograft models 57 PEGPH# 57 dose cohort 57 locoregional 57 metastatic malignant 57 chemotherapeutic regimens 57 sarcomatoid 57 PSMA ADC 57 HBeAg positive 57 FOLFOX 57 surgical debulking 57 nucleotide analog 57 Carfilzomib 57 dasatinib 57 leukemic cell 57 obatoclax 57 Preclinical studies 57 severe neutropenia 57 dasatinib Sprycel 57 recanalization 57 CBLC# 57 hypoperfusion 57 antibody titers 57 graft occlusion 57 CMV disease 57 interferon ribavirin 57 tamoxifen therapy 57 papillary renal cell carcinoma 57 achieved CCyR 57 cyclophosphamide 57 Symadex 57 antibody responses 57 bexarotene 57 indolent NHL 57 pharmacodynamic profile 57 mouse xenograft models 57 masitinib 57 INGN 57 mapatumumab 57 mCRC patients 57 virologic breakthrough 57 tumor regrowth 57 log# reduction 57 TELCYTA 57 adrenalectomy 57 hypercalcemia 57 rituximab 57 viremia 57 SUVmax 57 Seliciclib 57 PI3K inhibitor 57 brain metastases 56 TIMP 1 56 mRNA expression 56 nucleoside analogues 56 IL 1ß 56 plus methotrexate 56 SIV infection 56 vitro studies 56 PRT# 56 GISTs 56 activin 56 immunoreactivity 56 imatinib 56 GHRH 56 nephrotoxicity 56 Response Evaluation Criteria 56 heterozygotes 56 clodronate 56 hA# 56 Thrombocytopenia 56 recurrent glioblastoma multiforme 56 lenalidomide dexamethasone 56 myeloablative 56 rapid virologic response 56 recurrent VTE 56 APOPTONE 56 panobinostat 56 lymphocytosis 56 Fludara 56 recurrent GBM 56 cytokine refractory 56 HGS# 56 liver histology 56 antiviral efficacy 56 FDG uptake 56 SSc 56 neoadjuvant therapy 56 humoral antibody 56 QTc prolongation 56 cabazitaxel 56 cerebral ischemia 56 RECIST 56 epirubicin 56 glucose lowering 56 8mg/kg 56 CANCIDAS 56 dosing cohorts 56 IV NSCLC 56 interferon alfa 56 azacitidine 56 fibrotic disease 56 achieved ACR# 56 undetectable HBV DNA 56 gemcitabine Gemzar 56 androgen deprivation 56 hTERT 56 ganetespib 56 erlotinib Tarceva ® 56 anthracycline taxane 56 HCV RNA 56 pro apoptotic 56 TRIOLEX 56 sulfasalazine 56 osteosarcomas 56 APTIVUS r 56 dacarbazine DTIC 56 renal cell carcinomas 56 ON #.Na 56 fulvestrant 56 GIST tumors 56 corrected QT interval 56 T#I mutation 56 inhibitory activity 56 nanomolar 56 IOP lowering 56 pertuzumab 56 mg/m2 dose 56 H. pylori eradication 56 neurotoxicity 56 virologic failure 56 ara C 56 lesional 56 IMGN# 56 FOLFOX6 56 ALT flares 56 amrubicin 56 DMARDs 56 metastatic lesion 56 bronchodilation 56 idarubicin 56 prednisone prednisolone 56 FOLFOX chemotherapy 56 pneumonectomy 56 vitro cytotoxicity 56 antiandrogen 56 systemic ALCL 56 PXD# 56 hour bronchodilation 56 CLL cells 56 cisplatin 56 distant metastases 56 refractory NSCLC 56 R0 resection 56 OncoVEX GM CSF 56 EUS FNA 56 c MYC 56 overexpression 56 nilotinib 56 interferon alpha 56 refractory CTCL 56 transfected cells 56 induce apoptosis 56 MabCampath 56 doxorubicin cyclophosphamide 56 nonsense mutation 56 dasatinib Sprycel ® 56 ErbB2 positive 56 CHOP chemotherapy 56 mRCC 56 CDK4 56 cilengitide 56 serum HBV DNA 56 OHR/AVR# 56 visceral metastases 56 TMC# r 56 tumorigenicity 56 interleukin IL -# 56 EOquin TM 56 #mg/m# [001] 56 HCV genotypes 56 anti VEGF 56 syngeneic 55 HSCT 55 PEG IFN 55 Cyclin E 55 pharmacodynamic PD 55 Solid Tumors criteria 55 PGE2 55 underwent resection 55 induces apoptosis 55 standard chemotherapy regimens 55 dexamethasone Decadron 55 carcinoid 55 erlotinib 55 platinum refractory 55 CLL SLL 55 metastatic CRC 55 Telintra 55 genotypic resistance 55 murine 55 resected pancreatic cancer 55 ertapenem 55 dosage regimens 55 caspofungin 55 sorafenib Nexavar ® 55 overexpressing 55 free survival PFS 55 chronic GVHD 55 refractory AML 55 Etoposide 55 oral prodrug 55 Kaplan Meier analysis 55 PEG SN# 55 cidofovir 55 basal cell carcinoma BCC 55 pegylated interferon 55 Xanafide 55 VEGFR2 55 molecularly targeted 55 hematological toxicity 55 gemcitabine Gemzar ® 55 crizotinib PF # 55 relapsed SCLC 55 radiochemotherapy 55 antiangiogenic 55 chemotherapy regimens 55 tyrosine kinase inhibitors 55 antiproliferative effects 55 interferon alfa 2b 55 colon carcinoma 55 oral FTY# 55 fosamprenavir 55 fosbretabulin 55 GLYX 55 Traficet EN 55 relapsed CLL 55 neutralizing antibody 55 serum phosphate 55 antisense inhibition 55 Xelox 55 EBRT 55 TNF α 55 annualized relapse 55 plus ribavirin 55 mCi kg 55 hepatic fibrosis 55 anti TNF 55 collagen degradation 55 BRAF mutation 55 HGS ETR2 55 RECIST Response Evaluation Criteria 55 interferon beta 55 imatinib Gleevec 55 immunized mice 55 breast carcinoma 55 EGFR mutations 55 fluorouracil 55 depsipeptide 55 aminotransferases 55 IMC A# 55 concurrent chemoradiation 55 micafungin 55 antiangiogenic therapy 55 debulking surgery 55 fibrinolysis 55 oral allopurinol 55 pharmacodynamic effects 55 mcg BID 55 preclinical efficacy 55 circulating EPCs 55 IFN beta 55 parkinsonian symptoms 55 CRu 55 PSA nadir 55 calcitriol 55 Aptivus ® 55 experimental autoimmune encephalomyelitis 55 HER2 positive cancers 55 steatohepatitis 55 Bortezomib 55 flavopiridol 55 metastatic tumors 55 relapsed AML 55 SCCHN 55 GvHD 55 angiogenesis inhibitor 55 metastatic renal cell carcinoma 55 metastatic malignant melanoma 55 VEGF inhibition 55 infarct size 55 IGF 1R 55 FasL 55 prior chemotherapy regimens 55 trastuzumab Herceptin R 55 dexpramipexole 55 nephrectomy 55 Interferon alpha 55 metastases 55 MGd 55 virologic 55 mitoxantrone 55 Aflibercept 55 sunitinib 55 Gleevec resistant 55 NOD SCID mice 55 Toxicities 55 intratumoral injection 55 median PFS 55 infarcts 55 systemic absorption 55 chronic lymphocytic leukemia CLL 55 microglial activation 55 certolizumab 55 administered subcutaneously 55 thalidomide Thalomid 55 seroconversion 55 Trastuzumab 55 SERCA2a 55 standard chemotherapy regimen 55 mTOR inhibition 55 engraftment 55 PC# cells 55 NLX P# 55 gout flares 55 xenografts 55 atherosclerotic lesions 55 myocardial reperfusion 55 cranial radiation 55 Flu Cy 55 paclitaxel cisplatin 55 overlapping toxicities 55 Peg IFN 55 HBeAg positive patients 55 rFVIIa 55 nitazoxanide 55 plasma pharmacokinetics 55 Cyclin D1 55 CD# mAb 55 nutlin 3a 55 alicaforsen enema 55 receptor tyrosine kinase inhibitor 55 liposomal formulation 55 idraparinux 55 salmeterol HFA MDI 55 K ras mutations 55 glycated hemoglobin levels 55 interferon therapy 55 ribavirin therapy 55 docetaxel Taxotere ® 55 goserelin 55 olmesartan 55 IMA# 55 Irinotecan 55 antiangiogenic agents 55 E#F# 55 receiving VICTRELIS 55 biodistribution 55 GRN# 55 pharmacodynamic 55 lytic 55 mg administered orally 55 refractory CLL 55 RSV infection 55 mGluR5 antagonist 55 commonly mutated genes 55 fibrinolytic 55 ImmunoVEX HSV2 55 TRAIL induced apoptosis 55 medullary thyroid cancer 55 taxane chemotherapy 55 amyloid deposition 55 DMARD 55 AAV2 55 doxorubicin docetaxel 55 alkaline phosphatase ALP 55 SUTENT 55 ProSavin 55 mucosal healing 54 trans retinoic acid 54 temsirolimus 54 anticancer activity 54 corticosteroid therapy 54 platelet reactivity 54 chemoresistant 54 dose cyclophosphamide 54 NSCLC 54 doxorubicin 54 preclinically 54 antiandrogens 54 pegylated interferon alpha 54 lymphocyte counts 54 DLBCL 54 platelet dysfunction 54 fluvastatin 54 PKCi 54 Kinoid 54 anthracycline containing 54 repigmentation 54 Myelodysplastic Syndrome MDS 54 Hepatocellular Carcinoma HCC 54 subcutaneous injections 54 interferon 54 alemtuzumab treated 54 Kantarjian 54 nonclinical studies 54 Pharmacokinetics PK 54 DNA demethylation 54 octreotide LAR 54 intradermal injections 54 exemestane 54 IL 1beta 54 histologically 54 lymph node dissection 54 pheochromocytoma 54 timepoints 54 glioblastoma 54 WT1 54 docetaxel 54 receiving golimumab 54 IGFBP 3 54 pan HDAC inhibitor 54 CRLX# 54 myelosuppression 54 trabedersen 54 TTF Therapy 54 severe rotavirus gastroenteritis 54 cystectomy 54 Pegylated Interferon 54 Median survival 54 breast carcinomas 54 bladder tumors 54 olaparib 54 thrombotic complications 54 recurrent glioblastoma 54 effector function 54 cardiac dysfunction 54 immunomodulatory therapy 54 samalizumab 54 EGFR receptor 54 vivo potency 54 galiximab 54 epigenetic silencing 54 pharmacokinetic interactions 54 null responders 54 Akt activation 54 bone marrow suppression 54 Hematologic toxicity 54 tumoral 54 seropositive patients 54 HCV infected 54 potent anti angiogenic 54 low dose cytarabine 54 neutrophil counts 54 TEAEs 54 serum clusterin levels 54 erythropoietic 54 paclitaxel chemotherapy 54 lymphopenia 54 humoral immune responses 54 ZOLINZA 54 carcinoids 54 darunavir ritonavir 54 mycophenolate mofetil 54 AZT zidovudine Retrovir 54 neovascularization 54 metaglidasen 54 GRNOPC1 cells 54 paclitaxel Taxol ® 54 reinfarction 54 Aurora kinase 54 circulating lymphocytes 54 severe hypersensitivity reactions 54 TKI therapy 54 stage IIIb 54 Helicobacter infection 54 T#I [002] 54 ductal adenocarcinoma 54 5-fluorouracil/leucovorin 54 retapamulin 54 febrile neutropenia 54 refractory acute myeloid 54 blastic phase 54 peginterferon 54 trastuzumab 54 iniparib BSI 54 Dose escalation 54 PRADAXA #mg 54 IFN ß 54 renal flares 54 androgen ablation 54 PLX# 54 NF kappaB activation 54 TET2 54 HBeAg negative patients 54 elotuzumab 54 chemo radiotherapy 54 thrombocytopenic patients 54 lymphadenectomy 54 zoledronate 54 adipogenic 54 Epratuzumab 54 cediranib 54 dose dexamethasone 54 ipsilateral stroke 54 afatinib 54 ascending dose 54 endometrial hyperplasia 54 adjuvant tamoxifen 54 Valortim R 54 cerebral vasospasm 54 recurrent NSCLC 54 GnRH agonist 54 liposomal doxorubicin 54 gene rearrangements 54 5 Fluorouracil 54 OMP #M# 54 #mg BID [003] 54 metastatic renal cell 54 seroprotection 54 Thal Dex 54 intravascular hemolysis 54 plasma HCV RNA 54 clinically meaningful improvements 54 endometrial carcinoma 54 HBV DNA levels 54 SGS# 54 cetuximab 54 5-FU/LV 54 rt PA 54 NSCLC tumors 54 rituximab refractory 54 pharmacokinetic characteristics 54 colorectal tumor 54 GMX# 54 LY# [003] 54 rtPA 54 peg interferon 54 cytoprotective 54 immunosuppressive regimens 54 Folfox 54 oral diclofenac 54 Cotara 54 detectable HCV RNA 54 tumor xenografts 54 symptomatic VTE 54 tafamidis 54 peritoneal carcinomatosis 54 bicalutamide 54 renal toxicity 54 leukemia CLL 54 inotropic 54 cancer mCRC 54 MALT lymphoma 54 cisplatin gemcitabine 54 tamponade 54 hepatocellular carcinomas 54 mutant p# 54 HuMax EGFr 54 fluorouracil leucovorin 54 Clusterin 54 solithromycin 54 intradermal injection 54 synthase TS 54 radiotherapy RT 54 relapsed refractory 54 gefitinib 54 Decitabine 54 anthracycline 54 Azedra 54 pelvic lymphadenectomy 54 operable breast cancer 54 IRX 2 54 inducing apoptosis 54 Tamibarotene 54 temozolomide 54 HBeAg 54 metastatic melanoma 54 biologic DMARD 54 thromboembolic events 54 potent cytotoxic 54 radioiodine therapy 54 folinic acid 54 GVAX 54 Alocrest 54 viral kinetic 54 JMML 54 differentiated thyroid 54 hepatic metastases 54 Imprime PGG 54 BNC# 54 oral Hycamtin 54 Cisplatin 54 clinically localized prostate 54 lactate dehydrogenase 54 castrate resistant 54 CCX# 54 antiproliferative activity 54 Free Survival PFS 54 Immunohistochemical staining 54 neuronal dysfunction 54 haematologic 54 TORISEL 54 remission induction 54 pharmacokinetic PK 54 gene amplification 54 pT2 54 FDG-PET/CT 54 serum urate levels 54 alvespimycin 54 ependymoma 54 FOLPI regimen 54 ACR# responses 54 adrenal suppression 54 induced apoptosis 54 Phase 2a trial 54 ectopic expression 54 biochemical recurrence 54 paricalcitol 54 TGF beta signaling 54 F FDG PET 54 sorafenib Nexavar 54 relapsing remitting 54 MGUS 54 HCV infection 54 EDSS scores 54 recurrent malignant glioma 54 BCR ABL 54 SCH # 54 serologically active SLE 54 HDAC inhibition 54 SVR# 54 cell lysis 54 intracoronary 53 microbiological eradication 53 IFN γ 53 ALND 53 ritonavir boosted 53 KRAS oncogene 53 HIV RNA 53 lung tumors 53 arsenic trioxide 53 metastatic disease 53 talabostat 53 ERK1 2 53 LHRH analogues 53 severe exacerbations 53 pulmonary artery banding 53 JAK2 V#F 53 paclitaxel Taxol 53 MS relapses 53 missense mutations 53 gastric adenocarcinoma 53 antithymocyte globulin 53 elagolix 53 Dasatinib 53 pharmacokinetic PK study 53 #F FDG PET 53 uric acid lowering 53 neuroblastoma cells 53 QT QTc 53 Cytoxan 53 nonmelanoma skin cancers 53 toxicities 53 LEXIVA r 53 bone resorption 53 underwent surgical resection 53 platelet inhibition 53 parathyroidectomy 53 squamous histology 53 vivo 53 tumors GIST 53 potently inhibited 53 Partial Response 53 MYCN amplification 53 chemotherapy gemcitabine 53 AEG# 53 hypermethylation 53 invasive ductal 53 hepatoma 53 melphalan prednisone 53 relapsed refractory multiple myeloma 53 VcMP 53 HIV HCV coinfected 53 SIV infected 53 DOXIL 53 CMV infections 53 VEGF receptor 53 pancytopenia 53 dose proportionality 53 lymphomas 53 papillary RCC 53 intratumoral 53 imatinib Gleevec ® 53 LHRH antagonists 53 endophthalmitis 53 Apoptone 53 tiotropium 53 HCV replicon 53 NMIBC 53 androgen independent 53 imipenem 53 forodesine 53 TNF alpha antagonist 53 KRAS mutant tumors 53 thyroid carcinoma 53 Cloretazine 53 heparanase 53 PEGylated interferon beta 1a 53 timepoint 53 Eg5 53 mammographic density 53 anti proliferative 53 antiviral potency 53 homozygotes 53 mitoxantrone chemotherapy 53 refractory gout 53 anti EGFR antibody 53 medulloblastoma 53 VP# [004] 53 lymphadenopathy 53 arsenic trioxide ATO 53 tumor lysis syndrome 53 VELCADE melphalan 53 S/GSK# 53 antiretroviral naive 53 alfa 2a 53 tolvaptan 53 elevated ALT 53 cardiotoxic 53 survivin 53 MetMAb 53 plus MTX 53 leukaemias 53 vinca alkaloid 53 FOLPI 53 isoenzyme 53 phase IIb study 53 ELACYT 53 pulmonary metastasis 53 REYATAZ r arm 53 tumors 53 lymph node involvement 53 intraventricular 53 neutropenic patients 53 bortezomib Velcade 53 oncomodulin 53 prolongs survival 53 PSN# [002] 53 chemotherapy docetaxel 53 G CSF 53 anti angiogenic 53 AP# [003] 53 nucleoside naive patients 53 preclinical studies 53 paroxysmal AF 53 treatment naive genotype 53 phase IIb clinical 53 fondaparinux 53 mutated K ras 53 colorectal carcinoma 53 TNF antagonist 53 velafermin 53 HER2 positive tumors 53 Ophena TM 53 BCG refractory 53 virologic suppression 53 thymoma 53 bevacizumab Avastin ® 53 transarterial chemoembolization 53 taxane therapy 53 placebo dexamethasone

Back to home page